A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

► A6 demonstrated minimal activity in this study of recurrent or persistent epithelial ovarian, primary peritoneal, and fallopian tube carcinoma patients. ► We were unable to associate CD44 expression with progression free survival at six months.